Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis.
Asian Pac J Allergy Immunol
; 2021 Apr 18.
Article
em En
| MEDLINE
| ID: mdl-33865299
ABSTRACT
BACKGROUND:
The Center for Disease Control and Prevention (CDC) has mentioned Coronavirus Disease 2019 (COVID-19) patients with moderate or severe asthma as a high risk group for severe illness. While WHO mentioned only chronic respiratory diseases, not specifically asthma as a risk factor for severe illness. There has been asthma prevalence discrepancy in studies of COVID-19 across the world.OBJECTIVE:
This meta-analysis aims to investigate the association between asthma and composite poor outcome in patients with coronavirus disease (COVID-19).METHODS:
We conducted a systematic literature search from PubMed and Embase database. We included all original research articles with adult COVID-19 patients > 18 years old and had information related to asthma as a risk factor. Studies with outcomes consisting of mortality, severe COVID-19, use of mechanical ventilation, ICU admission, and hospital admission were included in this study. The outcomes of interest were divided into severe COVID-19, mortality and other poor outcomes.RESULTS:
Eleven studies were included in meta-analysis with a total of 6,046 patients. Asthma was not associated with composite poor outcomes with OR = 0.92 (95%CI 0.71-1.19, p = 0.61, and I2 = 8.49%). Furthermore, subgroup analysis showed that asthma was not associated with severe COVID (p = 0.76), mortality (p = 0.45), and other poor outcomes (p = 0.28).CONCLUSIONS:
Our study showed that asthma was not associated with severe COVID-19, mortality, and other poor outcomes in patients with COVID-19.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article